All-time High
$4.74
May 01, 2024
-91.11%(1d)
All-time Low
$0.44
Jun 17, 2025
-4.86%(1d)
Volume(24h)
$0
{{decimal(volume_24h_change,false,2)}}%(1d)
Turnover rate
0%
Market Cap
$3.2798M
FDV
$3.3M
Circulating supply
$0
Total supply
$7.78M
Max supply
7.78M
Tags
Margaritis Tags
Socials
Contracts
Explorers
Currency Calculator
{{conversion_one_currency}}
USD
CNY
JPY
KRW
TWD
CAD
EUR
GBP
DKK
HKD
AUD
BRL
CHF
CLP
CZK
DKK
{{conversion_two_currency}}
USD
CNY
JPY
KRW
TWD
CAD
EUR
GBP
DKK
HKD
AUD
BRL
CHF
CLP
CZK
DKK
Community sentiment
26%
74%
Bullish
Bearish
Justin Sun v Vitalik Buterin: Let’s break it down: $TRX: 
Near zero transaction cost Near instant transaction speed USDT dominance (one of the most used chains for Tether globally) High throughput - strong performance for payments and simple smart contract
Near zero transaction cost Near instant transaction speed USDT dominance (one of the most used chains for Tether globally) High throughput - strong performance for payments and simple smart contract 
Artificial Superintelligence Alliance Community Hotspots
Margaritis News
Apr / 24
-
- GeneVentiv Obtains $2.5 Million SBIR Grant to Develop Hemophilia Gene Therapy
- Apr 24, 2024 at 08:00 pm
- GeneVentiv Therapeutics has received a $2.5 million grant to conduct preclinical tests on its one-time infusion gene therapy for hemophilia A and B, with or without clotting factor inhibitors. The therapy, GENV-HEM, will be tested in a large study with a canine model of hemophilia, following promising results in mouse models of both hemophilia types. Funds will also be used to evaluate the gene therapy's distribution in the body and associated toxicology. These studies are expected to support a future investigational new drug application for the therapy.
